First Midwest Bank Trust Division increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,646 shares of the medical research company’s stock after acquiring an additional 125 shares during the quarter. First Midwest Bank Trust Division’s holdings in Amgen were worth $1,878,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in AMGN. Arlington Partners LLC boosted its stake in shares of Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after acquiring an additional 65 shares in the last quarter. Contravisory Investment Management Inc. acquired a new position in shares of Amgen during the 4th quarter worth approximately $50,000. Moody National Bank Trust Division bought a new position in Amgen in the 4th quarter valued at approximately $81,000. Mainstay Capital Management LLC ADV acquired a new stake in Amgen in the second quarter worth $111,000. Finally, Polaris Greystone Financial Group LLC bought a new stake in Amgen in the third quarter worth about $166,000. Institutional investors and hedge funds own 76.86% of the company’s stock.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $202.88, for a total transaction of $360,517.76. Following the transaction, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total transaction of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares in the company, valued at approximately $5,662,786.39. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by corporate insiders.
Several brokerages have recently weighed in on AMGN. Citigroup upped their target price on Amgen from $200.00 to $204.00 and gave the stock a “neutral” rating in a research note on Thursday, November 1st. Royal Bank of Canada reissued a “neutral” rating and issued a price objective on shares of Amgen in a report on Monday, January 14th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, January 14th. Goldman Sachs Group reiterated a “buy” rating and issued a $232.00 target price on shares of Amgen in a research note on Tuesday, December 4th. Finally, reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Monday, October 1st. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Amgen currently has an average rating of “Hold” and a consensus target price of $205.50.
NASDAQ:AMGN opened at $203.88 on Friday. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. The stock has a market capitalization of $129.92 billion, a PE ratio of 16.21, a price-to-earnings-growth ratio of 2.04 and a beta of 1.32. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. Amgen’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.27 EPS. On average, analysts forecast that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be issued a dividend of $1.45 per share. This is an increase from Amgen’s previous quarterly dividend of $1.32. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $5.80 annualized dividend and a yield of 2.84%. Amgen’s dividend payout ratio is currently 41.97%.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/01/20/first-midwest-bank-trust-division-has-1-88-million-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.